% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Morbelli:889138,
author = {Morbelli, Silvia and Esposito, Giuseppe and Arbizu, Javier
and Barthel, Henryk and Boellaard, Ronald and Bohnen, Nico
I. and Brooks, David J and Darcourt, Jacques and Dickson,
John C. and Douglas, David and Drzezga, Alexander and
Dubroff, Jacob and Ekmekcioglu, Ozgul and Garibotto,
Valentina and Herscovitch, Peter and Kuo, Phillip and
Lammertsma, Adriaan and Pappata, Sabina and Peñuelas, Iván
and Seibyl, John and Semah, Franck and Tossici-Bolt, Livia
and Van de Giessen, Elsmarieke and Van Laere, Koen and
Varrone, Andrea and Wanner, Michele and Zubal, George and
Law, Ian},
title = {{EANM} practice guideline/{SNMMI} procedure standard for
dopaminergic imaging in {P}arkinsonian syndromes 1.0},
journal = {European journal of nuclear medicine and molecular imaging},
volume = {47},
number = {8},
issn = {1619-7089},
address = {Heidelberg [u.a.]},
publisher = {Springer-Verl.},
reportid = {FZJ-2021-00063},
pages = {1885 - 1912},
year = {2020},
abstract = {PurposeThis joint practice guideline or procedure standard
was developed collaboratively by the European Association of
Nuclear Medicine (EANM) and the Society of Nuclear Medicine
and Molecular Imaging (SNMMI). The goal of this guideline is
to assist nuclear medicine practitioners in recommending,
performing, interpreting, and reporting the results of
dopaminergic imaging in parkinsonian
syndromes.MethodsCurrently nuclear medicine investigations
can assess both presynaptic and postsynaptic function of
dopaminergic synapses. To date both EANM and SNMMI have
published procedural guidelines for dopamine transporter
imaging with single photon emission computed tomography
(SPECT) (in 2009 and 2011, respectively). An EANM guideline
for D2 SPECT imaging is also available (2009). Since the
publication of these previous guidelines, new lines of
evidence have been made available on semiquantification,
harmonization, comparison with normal datasets, and
longitudinal analyses of dopamine transporter imaging with
SPECT. Similarly, details on acquisition protocols and
simplified quantification methods are now available for
dopamine transporter imaging with PET, including recently
developed fluorinated tracers. Finally, [18F]fluorodopa PET
is now used in some centers for the differential diagnosis
of parkinsonism, although procedural guidelines aiming to
define standard procedures for [18F]fluorodopa imaging in
this setting are still lacking.ConclusionAll these emerging
issues are addressed in the present procedural guidelines
for dopaminergic imaging in parkinsonian syndromes.},
cin = {INM-2},
ddc = {610},
cid = {I:(DE-Juel1)INM-2-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572) / 573 -
Neuroimaging (POF3-573)},
pid = {G:(DE-HGF)POF3-572 / G:(DE-HGF)POF3-573},
typ = {PUB:(DE-HGF)16},
pubmed = {32388612},
UT = {WOS:000531214000004},
doi = {10.1007/s00259-020-04817-8},
url = {https://juser.fz-juelich.de/record/889138},
}